<DOC>
	<DOCNO>NCT00822861</DOCNO>
	<brief_summary>During propose clinical trial , investigator intend evaluate pharmacodynamic anti-inflammatory property safety TPI ASM8 , investigate effect sputum eosinophils airway response allergen challenge different dose level .</brief_summary>
	<brief_title>Efficacy Safety Four Escalating Dose Regimens TPI ASM8 Patients With Allergic Asthma</brief_title>
	<detailed_description>The early late asthmatic response significantly attenuate high dose ASM8 . The methacholine challenge parameter ( ECP , mRNA knockdown CCR3 B-Chain IL-3-Il-5 GMCSF attenuate ASM8 .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Men woman 18 65 year age Generally good health ; steroid naïve ( take inhaled/oral corticosteroid within last month ) mild moderate , stable , allergic asthma define ATS criterion History episodic wheeze shortness breath Forced expiratory volume one second ( FEV1 ) baseline ≥ 70 % predict value Able comprehend follow require study procedure ; willing able sign inform consent form . Significant acute chronic medical psychiatric illness Known coagulopathy , worsen asthma respiratory infection precede 6 week Use inhale oral corticosteroid within last 30 day , need antihistamine within 72 hour allergen methacholine challenge , immunosuppressive , nonsteroidal antiinflammatory drug , anticoagulant ( intermittent dos shortacting β2agonist allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>